ClinicaliQ Trial Snapshot
- Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease — Recruiting • Phase I • NCT07228364.
- Drug being tested: AZD1613 is undergoing evaluation for safety, tolerability, and pharmacokinetics via subcutaneous or intravenous administration in adults with autosomal dominant polycystic kidney disease (ADPKD).
- Patient eligibility overview: The trial enrolls adults with confirmed ADPKD, with assessment of safety and dosing tolerance across different administration routes to establish optimal therapeutic delivery.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Eligibility Snapshot
- : * Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes * eGFR = 45 to 90 mL/min /1.73m2 * Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg/m2 (inclusive). * Females are to be of non-childbearing potential
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.